BridgeBio Pharma stock price target raised to $86 from $56 at Mizuho

1 BUSINESS

Business News - Opportunities - Reviews

 

 

BridgeBio Pharma Inc.

BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply